statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of...

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Needham  Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT - Free Report) in a research note issued to investors on Monday, Benzinga reports. They...

Phathom Pharmaceuticals (NASDAQ:PHAT) Given Buy Rating at Needham & Company LLC

FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT  Get Free Report) insider Terrie Curran sold 16,851 shares of the businesss stock in a transaction on Friday, March 22nd. The stock was sold...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells $153,512.61 in Stock

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Phathom Pharmaceuticals launches direct-to-consumer campaign

National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA (vonoprazan), the first and only FDA-approved...

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign,  VOQUEZNA Can Kick Some Acid

This is a signal that PHAT's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Phathom Pharmaceuticals (PHAT, $10.45) RSI Indicator left the overbought zone on March 25, 2024

This price move could be a signal that PHAT may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Phathom Pharmaceuticals (PHAT, $11.02) price may drop as it broke higher Bollinger Band on Mar 22, 2024

Phathom Pharmaceuticals (PHAT, $11.02) RSI Indicator left the overbought zone on March 22, 2024

This is a Bullish indicator signaling PHAT's price could rise from here. Traders may explore going long the stock or buying call options...

Phathom Pharmaceuticals (PHAT, $11.02) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Volume	647,444.00
52-Wk High	$17.02
52-Wk Low	$6.07

Period	Estimated	Reported	Surprise	Result
Q1'24	-$1.32	--	--	N/A
Q4'23	-$1.08	-$1.39	-29.05%	MISSED
Q3'23	-$0.89	-$0.76	14.77%	BEAT
Q2'23	-$0.98	-$0.84	14.14%	BEAT
Q1'23	-$1.26	-$0.89	29.39%	BEAT

PHAT Phathom Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals